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ABSTRACT
The aim of the present study was to develop microemulsion gel of Satranidazole for the treatment of periodontitis. The 
objective was to increase the solubility of Satranidazole, a lipophilic drug and to enhance depth of penetration of the drug 
into the periodontal pocket for efficacious treatment of periodontitis. Pseudo ternary phase diagrams were constructed to 
determine the region of existence of microemulsions prepared using cosurfactant titration method. The formulations were 
developed using isopropyl myristate, tween 80, ethanol; oleic acid, tween 80, propylene glycol; oleic acid, cremophor RH 
40, ethanol. Optimization of formulations was done based on in vitro diffusion studies. The microemulsion was gelled using 
carbopol 940 as the gelling agent. The formulations were evaluated for pH, viscosity, percent transmittance, centrifugation 
(phase separation), and characterized by scanning electron microscopy, particle size, zeta potential and polydispersity index. 
The formulation inhibited the growth of micro organism, Salmonella typhimurium which indicates that the formulation 
could be used to treat periodontal infection.
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INTRODUCTION
Periodontal  disease  could  be  defined  as  a  disorder  of 
supporting  structures  of  teeth,  including  the  gingival, 
periodontal  ligament  and  alveolar  bone.
[1] Periodontal 
disease results in loss of connective tissue and bone support 
and is a major cause of tooth loss in adults.
[2]
The  current  practice  for  the  treatment  of  periodontitis 
involves scaling and root planing followed by administration 
of systemic antibiotics or application of local antibiotics like 
metronidazole  gel  directly  on  the  gums  several  times  as 
adjuncts to conventional mechanical therapy.
[3-4] Although 
systemic administration of antibiotics has advantages of easy 
and simple administration, this route of administration poses 
some  disadvantages  like  uncertain  patient  compliance, 
inability  of drugs to achieve adequate  concentration at  the 
site  of  infection,  increased  risk  of  adverse  drug  reactions, 
development of resistance by various micro organisms and 
effects of systemic antibiotics on extraoral bacteria.
[4] These 
disadvantages  have  led  to  the  development  of  local 
application of antibiotics which are intended to exclusively 
affect bacteria within the periodontal pocket.
[5]
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Metronidazole  gel  is  a  very  bitter  formulation  and, thus, 
reduces  patient  compliance.  Satranidazole  is  a  5-
nitroimidazole  derivative  that has  been  found  to  be  more 
active  against  aerobic,  microaerophilic,  and  anaerobic 
bacteria than Metronidazole. The MIC90 of Satranidazole was 
found  to  be  fourfold  lower  than  Metronidazole  against  50 
clinical  isolates  of  anaerobes.
[3] The  literature  survey 
indicates  that  Satranidazole,  inspite  of  its  therapeutic 
efficacy,  is  not  explored  effectively for  the  treatment  of 
periodontal  disease.  Therefore,  we  focussed  on  the 
microemulsion gels of Satranidazole in our present study.
Microemulsions  are  clear,  thermodynamically  stable, 
isotropic mixtures of oil, water and surfactant, frequently in 
combination  with a  cosurfactant.
[6] In  case  of  periodontal 
delivery, microemulsion can overcome the problem with the 
existing topical products (jelly,  ointment or spray) such as 
lack of efficacy due to inadequate depth of penetration, too 
short  duration  and  difficulties  in  administration  due  to 
spread, taste etc. Microemulsion alone or in conjunction with 
in situ gelling system is a promising tool for drug delivery in 
periodontitis.
[7] Microemulsion gel offers advantage of long 
contact  time  with  the  periodontal  pocket  due  to  the 
mucoadhesive  polymer  used  as  a  gelling  agent  in  the 
formulation of microemulsion gel.
MATERIALS AND METHODS 
Satranidazole was obtained as a kind gift sample from Alkem 
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Cremophor  RH  40,  Ethanol,  Carbopol  940  were  obtained 
from  SD  Fine  Chemicals  Ltd.; Isopropyl  myristate  was 
obtained from NR Chem and Propylene glycol was obtained 
from Nice Chemicals Pvt. Ltd.
Solubility Studies 
The components  of microemulsion  were selected based  on 
solubility  studies.  Solubility  studies  were  conducted  by 
adding  excess  amount  of  Satranidazole  to  oils  (oleic  acid, 
isopropyl  myristate,  olive  oil  and  light  liquid  paraffin), 
surfactants (tween  80, tween  20, tween 60, cremophor  RH 
40, span  80), and cosurfactants (propylene  glycol,  ethanol, 
butanol, sorbitol) taken in vials. The vials were shaken on a 
rotary shaker (Table top orbital shaker, Eltek
®) for 48 hours. 
The  solutions  were  then  centrifuged  at  3000  rpm  for  15 
minutes  and  filtered  through  Whatman filter  paper.  The 
concentration  of  drug  in  each  of  the  components  was 
determined  using  UV-Visible  double  beam 
spectrophotometer (Lab India
®UV 3000
+) at a wavelength of 
318 nm.
Construction of phase diagram
Pseudo  ternary  phase  diagrams  were  constructed  to 
determine the area of microemulsion existence. This region 
was determined by cosurfactant titration method. Oil phase, 
Satranidazole, water and surfactant were mixed to form an 
emulsion. To this mixture, cosurfactant was added drop wise 
under continuous mechanical stirring. The contents of oil and 
water  were  varied from 9:1  to 1:9 ratio.  The  mixture  was 
visually examined for transparency following the addition of 
cosurfactant. Transparent, single phase, low viscous mixtures 
were designated as microemulsions.
Preparation of microemulsion  
Cosurfactant  titration  method  was  employed  for  the 
preparation  of  microemulsion.  The  concentrations  of  oil, 
water, surfactant and cosurfactant were varied in each case 
keeping  the  concentration  of  drug  constant.  Predetermined 
amount of drug was accurately weighed and dissolved in oil. 
Water and surfactant were added to oily solution of the drug
and mechanically stirred (Magnetic stirrer, Remi Equipments 
Pvt. Ltd.) to form an emulsion. Cosurfactant was added drop
wise  to  the  emulsion  till  the  formation  of  a  transparent 
mixture.  Formation  of  transparent  solution  indicates 
formation  of  microemulsion.
[8] The  details  of  the 
formulations are shown in Table 1.
Preparation of microemulsion gel 
Microemulsion gel was prepared using carbopol 940 as the 
gelling agent. Carbopol was hydrated by soaking in water for 
a period of 24 hours. Triethanolamine was then added to the 
swollen polymer to form a gel. Microemulsion was gelled by 
adding  the  aqueous  portion  (gelling  agent)  to  the  non-
aqueous  portion  (microemulsion)  with  continuous 
mechanical stirring.
[9-10]
Evaluation  and  Characterization  of
Microemulsion/Microemulsion Gel 
Percent transmittance 
Percent transmittance of the microemulsions was measured 
using  UV-Visible  double  beam  spectrophotometer  at  a 
wavelength of 560 nm. Keeping distilled water as blank.
Centrifugation
The microemulsions were centrifuged (Research Centrifuge, 
R  24,  Remi  Equipments  Pvt.  Ltd.)  at  9000  rpm  for  30 
minutes in order to eliminate metastable systems.
pH 
pH of the formulations was measured using digital pH meter 
(Digital pH meter, Model-112).
Viscosity 
Viscosity of microemulsions was measured using Brookfield 
digital viscometer (Brookfield viscometer, DV-II+ Pro) fitted 
with S-34 spindle at 5, 10, 20, 50 and 100 rpm.
Viscosity  of  microemulsion  gel  was  measured  using 
Brookfield digital viscometer fitted with S-64 spindle at 0.5, 
1, 2, 5, 10 and 12 rpm.
[8]
Morphology 
Morphology  of  the  microemulsion  was  studied  using 
Scanning Electron Microscopy (Hitachi S - 3700N).
[11]
Particle size and Zeta potential 
Particle size and zeta potential was measured using Malvern 
Nano (ZS) zeta sizer Ver. 6.20.
FTIR Studies 
Fourier  Transform  Infra  Red  analysis  was  conducted  to 
verify  the  possibility  of  interaction  of  chemical  bonds 
between drug and other excipients of the formulation. FTIR 
analysis  was  performed  using  Shimadzu  8400  S  FTIR
spectrophotometer. The samples were scanned in the spectral 
region of 4000-500 cm
-1. Solid samples were crushed, mixed 
with  potassium  bromide  and  pressed  at  15000  psig  using 
hydraulic press to make a disc. Gel samples were sandwiched 
between two IR transparent plates made up of KBr.
In-vitro drug release studies 
Drug release studies were performed using Franz diffusion 
cell  employing  a  dialysis  membrane  (dialysis  membrane-
135). Dialysis  membrane  was  initially  soaked  in  pH  6.8
Table 1: Formulation details of microemulsions showing concentration of each component in % w/w
Formulation code Isopropyl myristate Oleic acid Water Tween 80 Cremophor RH 40 Ethanol Propylene glycol
F1 44.73 - 4.97 15.80 - 34.50 -
F2 50.97 - 12.74 33.77 - 2.51 -
F3 25.02 - 10.72 21.97 - 42.29 -
F4 21.97 - 14.65 27.71 - 35.68 -
F5 17.53 - 17.53 31.89 - 33.06 -
F6 12.91 - 19.36 35.91 - 31.82 -
F7 9.86 - 23.02 13.94 - 53.18 -
F8 7.48 - 29.92 19.82 - 42.78 -
F9 7.48 - 40.28 19.93 - 35.31 -
F10 - 72.04 8.01 2.55 - - 17.41
F11 - 14.26 3.56 1.89 - - 80.29
F12 - 14.07 14.07 32.81 - - 39.06
F13 - 13.94 20.91 22.17 - - 42.97
F14 - 4.27 9.96 12.07 - - 73.71
F15 - 6.95 27.79 36.83 - - 28.43
F16 - 4.36 39.24 27.73 - - 28.68
F17 - 62.19 6.91 - 21.35 9.54 -
F18 - 46.61 11.65 - 30.01 11.72 -
F19 - 30.69 13.15 - 31.61 24.56 -Swaroopa et al. / Formulation, Evaluation and Characterization of Periodontal Microemulsion…..……
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phosphate buffer solution for 24 hours. It was then clamped 
between donor and receptor compartments of Franz diffusion 
cell.  The  receptor  compartment  was  filled  with  pH  6.8 
phosphate  buffer  solution  and  was  magnetically  stirred 
throughout  the  experiment.  The  donor  compartment 
contained appropriate amount of the formulation.
Aliquots (5 ml.) of sample were withdrawn from the receptor 
compartment at specified time intervals for 8 hours and were 
replaced  with  fresh  buffer  solution  to  maintain  sink 
conditions. The  samples  were  analyzed  for  drug 
concentration  using  UV-Visible  double  beam 
spectrophotometer.  The  drug  concentration  was  calculated 
using standard calibration curve.
Stability studies 
Stability  studies  of  the  developed  microemulsions  were 
carried  out  by  storing the  formulations  at  three  different 
temperatures for 3 months. The optimized formulations were 
stored  at  refrigerated condition  (2-8ºC),  room  temperature
(25±2ºC) and elevated temperature (50±2ºC). Stability of the 
stored formulations was evaluated by visually inspecting the 
formulations for phase separation or turbidity.
[8]
In-vitro Microbiological Evaluation of Microemulsion 
Formulation F13 was selected as the optimized formulation 
based  on in  vitro  diffusion studies. F13  was evaluated  for 
anti-microbial activity. The micro organism selected for the 
study  was  Salmonella  typhimurium.  The  bacterium  was 
subcultured  in  Luria  Bertia  broth  (LB  broth)  and  then 
transferred  onto  LB  agar  medium  to  carry  out 
microbiological evaluation of the formulation. Disc diffusion 
method was employed for the study.  Formulation F13 was 
employed as test and placebo was employed as control in the 
study.
[12]
RESULTS AND DISCUSSION 
Solubility studies
Solubility studies were conducted to determine solubility of 
the  drug  in  various oils,  surfactants  and  cosurfactants. 
Satranidazole  showed  high  solubility  in  oleic  acid  and 
isopropyl myristate among oils, in tween 80 and cremophor 
RH 40 among surfactants, in propylene glycol and ethanol 
among  cosurfactants.  Therefore,  oleic  acid  and  isopropyl 
myristate were selected as oil phase, tween 80 and cremophor 
RH 40 were selected as surfactants, and propylene glycol and 
ethanol were selected as cosurfactants for the formulation of 
microemulsions.  The  solubility  of  Satranidazole  in  various 
oils, surfactants and cosurfactants is shown in Table 2.
Construction of phase diagram 
Pseudo  ternary  phase  diagrams  were  constructed  using 
Chemix School Software Ver. 3.60 (2012).  Microemulsion 
existence  region  was then determined.  Fig.  1  describes
pseudo  ternary  phase  diagrams of  the  microemulsions
containing various weight ratios of (a) isopropyl myristate, 
water, tween 80 and ethanol (b) oleic acid, water, tween 80, 
propylene  glycol  (c)  oleic  acid,  water,  cremophor  RH  40, 
ethanol.  The  shaded  region  indicates  microemulsion 
existence region. The rest of the region represents turbid and 
conventional  emulsions  based  on  visual  inspection.  Phase 
diagram of isopropyl myristate, water, tween 80 and ethanol 
shows  highest  microemulsion  existence  region. This  could 
probably be due to greater solubility of the drug in tween 80.
Percent transmittance 
Percent transmittance of the microemulsions was measured 
using  UV-Visible  double  beam  spectrophotometer  at  a 
wavelength of 560 nm; keeping distilled water as blank. The 
results  are  shown  in  Table  3.  The  percent  transmittance 
results  revealed  that  microemulsions  were  transparent  like 
that of water.
Centrifugation 
The  microemulsions  were  centrifuged  at  9000  rpm  for  30 
minutes in order to eliminate metastable systems. No phase 
separation was observed after centrifugation which indicates
stability of the formulations.
Viscosity 
Viscosity of microemulsions was measured using Brookfield 
digital viscometer fitted with S-34 spindle at 5, 10, 20, 50 
and 100 rpm. Viscosity of microemulsion gel was measured 
using Brookfield digital viscometer fitted with S-64 spindle 
at 0.5, 1, 2, 5, 10 and 12 rpm. The results are shown in Tables 
4 and 5. The results indicate that microemulsions have low
viscosity and are Newtonian liquids.
pH 
pH was determined using digital pH meter. Average pH of 
the formulations was found to be 6.7. The results are shown 
in Table 6. The results indicate that pH of the formulations 
are  similar  to  that  of  buccal  cavity.  Thus,  the  formulation 
may not cause irritation.
Particle size, Zeta potential and Polydispersity index 
Fig. 2 and 3 show particle size distribution and zeta potential 
of the formulation F13. Particle size of the  microemulsion 
was found to be 369 nm and zeta potential was found to be -
0.0529  mV  which  indicates  that  the  particles  of 
microemulsion  are  negatively  charged  which  provide 
electrostatic  stabilization.  The  polydispersity  index  was 
found  to  be  0.317  which  indicates  narrow  particle  size 
distribution.
FTIR Studies 
FTIR analysis  was  conducted  to  verify  the  possibility  of 
interaction  of  chemical  bonds  between  drug  and  other 
excipients  of  the  formulation.  The  IR  spectrum  of drug, 
formulations F13 and F19 recorded by FTIR spectrometer are 
shown in fig. 4, 5 and 6. The spectra of the formulations were
Table 2: Solubility of Satranidazole in various components
Component Solubility (mg/ml)
Isopropyl myristate 0.2230 ± 0.011
Oleic acid 0.3750 ± 0.032
Olive oil 0.1919 ± 0.036
Light liquid paraffin 0.1714 ± 0.035
Cremophor RH 40 0.7624 ± 0.038
Tween 80 0.9671 ± 0.027
Tween 20 0.3521 ± 0.039
Tween 60 0.5329 ± 0.017
Span 80 0.4384 ± 0.038
Ethanol 1.3023 ± 0.077
Butanol 0.8451 ± 0.088
Propylene glycol 1.1368 ± 0.066
Sorbitol 0.5675 ± 0.044
Table 3: Percent transmittance values of F13 and F19
Formulation Percent transmittance
F13 98.6
F19 99.4
Table 4: Viscosity of F13 and F19 microemulsions
RPM
Viscosity (cps)
F13 F19
5 263.9 168
10 144 72
20 138 48
50 132 43.2
100 118.8 40.8Swaroopa et al. / Formulation, Evaluation and Characterization of Periodontal Microemulsion…..……
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Table 5: Viscosity of F13 and F19 microemulsion gel          
RPM
Viscosity (cps)
F13 F19
0.5 88301 33593
1 53988 18596
2 36232 15657
5 19532 10798
10 11566 9370
12 10048 8658
Table 6: pH of microemulsion and microemulsion gel
Formulation
pH
Microemulsion Microemulsion gel
F13 6.7 6.8
F19 6.6 6.6
Table 7: Stability studies of F13 and F19
Temperature
Phase separation/Turbidity
F13 F19
2-8ºC No Slight turbidity
Room temperature No No
Elevated temperature (50±2ºC) No No
Table 8: Cumulative percent drug release of optimized formulations
Time 
(min)
Microemulsions Microemulsion gel
F13 F19 F13 F19
0 0 0 0 0
15 3.3 ± 1.60 2.42 ± 0.81 2.42 ± 1.44 1.72 ± 0.57
30 7.64 ± 3.58 5.89 ± 1.81 6.02 ± 3.39 4.52 ± 1.20
45 11.75 ± 5.85 8.66 ± 2.61 8.09 ± 2.09 7.47 ± 1.43
60 15.91 ± 8.10 11.83 ± 3.36 12.28 ± 3.90 10.85 ± 1.59
120 20.94 ± 9.88 17.23 ± 2.90 17.11 ± 3.75 16.05 ± 2.68
180 27.84 ± 10.37 24.50 ± 3.59 24.34 ± 1.77 23.03 ± 4.24
240 36.58 ± 9.79 33.27 ± 4.37 32.43 ± 0.77 30.63 ± 4.72
300 47.43 ± 7.42 45.05 ± 3.65 42.13 ± 1.43 39.41 ± 4.57
360 56.31 ± 8.73 58.47 ± 4.27 52.64 ± 2.98 49.19 ± 4.14
420 76.03 ± 4.56 72.92 ± 3.97 65.30 ± 1.73 60.50 ± 4.51
480 93.72 ± 3.34 89.65 ± 3.52 79.64 ± 0.65 73.26 ± 3.26
(1a)
(1b)
(1c)
Fig. 1: Pseudoternary phase diagrams of (a) isopropyl myristate, water, 
tween 80, ethanol (b) oleic acid, water, tween 80, propylene glycol (c) 
oleic acid, water, cremophor RH 40, ethanol
Fig. 2: Particle size distribution of F13
Fig. 3: Zeta potential of F13
compared with that of Satranidazole. The characteristic peaks 
of  optimized  formulations  followed  the  same  trajectory  as 
that of drug alone with minor differences. Thus there may be 
no drug-excipient interactions.
In-vitro drug release studies 
Drug release studies were performed using Franz diffusion 
cell employing a dialysis membrane. pH 6.8 phosphate buffer 
was used as the release medium. Drug release was found to 
be  highest  for  the  formulations  F13  (93.72%)  containing 
13.94%  oleic  acid,  20.91%  water,  22.17%  tween  80  and 
42.97%  propylene  glycol and F19  (89.65%) containing 
62.19% oleic acid, 6.91% water, 21.35% cremophor RH 40 
and  9.54% ethanol. Hence,  these  formulations  were  gelled 
using carbopol 940 and drug release from the gels was less 
(79.64% (F13) and 73.26% (F19)) when compared to that of
microemulsions (Table 8).Swaroopa et al. / Formulation, Evaluation and Characterization of Periodontal Microemulsion…..……
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Fig. 4: FTIR image of Satranidazole
Fig. 5: FTIR image of F13
Fig. 6: FTIR image of F19
Fig. 7: SEM photograph of F13Swaroopa et al. / Formulation, Evaluation and Characterization of Periodontal Microemulsion…..……
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Fig. 8: Microbiological evaluation of formulation F13 showing zone of 
inhibition
Fig. 9: Cumulative percent drug release of optimized formulations
Fig. 10: Cumulative percent drug release of microemulsion gel
Morphology
Morphology  of  the  microemulsions  was  studied  using 
Scanning  Electron  Microscopy.  Fig.  7 shows  SEM 
photograph  of  formulation  F13.  The SEM  photograph 
indicates that the microemulsion contains spherical globules 
and no agglomerates were seen.
Stability studies
Stability  studies  were  conducted  to  evaluate  the 
microemulsions  for  phase  separation  or  turbidity. The 
optimized formulations were stored at refrigerated condition 
(2-8ºC),  room  temperature (25±2ºC) and  elevated 
temperature  (50±2ºC) for  3  months (Table  7).  The 
formulations were found to be stable as no phase separation 
or turbidity was observed in the formulations.
In-vitro microbiological evaluation of microemulsion 
The  optimized  formulation  F13  was  evaluated  for  anti-
microbial  activity.  The  activity  was  tested  against  the 
bacterium  Salmonella  typhimurium. The  formulation  F13 
inhibited growth of the bacterium and zone of inhibition was 
observed. The diameter of the zone of inhibition was found 
to  be  1.5  cm. The  formulation  inhibited  the  growth  of 
Salmonella typhimurium which indicates that the formulation 
could be used to treat periodontal infection.
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